MedicalResearch.com Interview with:
Dr. David Okonkwo, M.D., Ph.D.,
Professor of Neurological surgery
Director of the Neurotrauma Clinical Trials Center
University of Pittsburgh
Dr. Okonkwo discusses the results from the STEMTRA Phase 2 trial evaluating the efficacy and safety of SB623 in patients with chronic motor deficit from traumatic brain injury.
The results were presented at the American Association of Neurological Surgeons (AANS), April 2019
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Traumatic brain injury (TBI) is a major cause of death and disability in the US and around the globe. The effects of TBI are often long-lasting, with more than one-third of severe TBI patients displaying a neuromotor abnormality on physical examination 2 years following injury and, yet, there are no effective treatments. The public health implications are staggering: there are approximately 1.4 million new cases of TBI in the US annually, resulting in over 50,000 deaths and 80,000 disabilities; over 5 million Americans currently suffer from long-term disability caused by TBI. A successful neuroregenerative or neurorestorative therapy, such as stem cell implantation, would have significant impact.